|

PD-1 antibody Clinical Trials

12 actively recruiting trials

Also known as: Sintilimab, Tislelizumab, Toripalimab

Pipeline

Phase 2: 8Phase 3: 2Phase 1/2: 1Phase 2/3: 1

Top Sponsors

  • Fudan University7
  • Sir Run Run Shaw Hospital2
  • Sun Yat-sen University1
  • Sun Yat-Sen University Cancer Center1
  • N.N. Alexandrov National Cancer Centre1

Indications

  • Cancer12
  • Locally Advanced Rectal Cancer2
  • Rectal Cancer2
  • Persistent Cervical Cancer1
  • Low Rectal Cancer1

Other12 trials

CAPOX and PD-1 Antibody Combined With or Without Radiotherapy for MSS Locally Advanced Rectal Cancer
Phase 2
EGFR Antibody Combined With PD-1 Inhibitor and Chemotherapy in R/M Nasopharyngeal Carcinoma
Phase 1/2
Hypofractionated Radiotherapy Plus Immunotherapy Versus Conventional Radiotherapy in Locally Recurrent Rectal Cancer
Phase 2
MR-guided Adaptive Radiotherapy Combined With PD-1 Antibody and CAPOX for Locally Advanced Rectal Cancer
Phase 2
Metronomic Capecitabine With or Without PD-1 Antibody as Adjuvant Therapy in High-risk Nasopharyngeal Carcinoma
Phase 3
Node-sparing Short-Course Radiation Combined With CAPOX and Tislelizumab for MSS Rectal Cancer
Phase 3
Nodes-sparing Short-course Radiation Combined With CAPOX and Tislelizumab for MSS Middle and Low Rectal Cancer
Phase 2
PD-1 (Programmed Death-1) Versus PD-L1 (Programmed Death-ligand 1) Immune Check Point Inhibitors Combined With Chemotherapy, With or Without Bevacizumab, In Patients With Metastatic, Persistent Or Recurrent Cervical Cancer
Phase 2/3
Short-course Radiotherapy Combined With CapeOx and PD-1 Inhibitor After Local Excision for High-risk Early Rectal Cancer (TORCH-LE)
Phase 2
The Combination of Hypofractionated Radiotherapy and Immunotherapy in Locally Recurrent Rectal Cancer
Phase 2
The Combination of Immunotherapy and Neoadjuvant Short-course Radiotherapy in Early Rectal Cancer
Phase 2
Vebrekotuzumab ± Anti-PD-1 in Pretreated Advanced ESCC
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.